{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:35:02Z","timestamp":1790087702943,"version":"4.0.1"},"reference-count":159,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>The picture of HDL cholesterol (HDL-C) as the \u201cgood\u201d cholesterol has eroded. This is even more surprising because there exists strong evidence that HDL-C is associated with cardiovascular disease (CVD) in the general population as well as in patients with impairment of kidney function and\/or progression of CKD. However, drugs that dramatically increase HDL-C have mostly failed to decrease CVD events. Furthermore, genetic studies took the same line, as genetic variants that have a pronounced influence on HDL-C concentrations did not show an association with cardiovascular risk. For many, this was not surprising, given that an HDL particle is highly complex and carries &gt;80 proteins and several hundred lipid species. Simply measuring cholesterol might not reflect the variety of biologic effects of heterogeneous HDL particles. Therefore, functional studies and the involvement of HDL components in the reverse cholesterol transport, including the cholesterol efflux capacity, have become a further focus of study during recent years. As also observed for other aspects, CKD populations behave differently compared with non-CKD populations. Although clear disturbances have been observed for the \u201cfunctionality\u201d of HDL particles in patients with CKD, this did not necessarily translate into clear-cut associations with outcomes.<\/jats:p>","DOI":"10.1681\/asn.2017070798","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T10:54:24Z","timestamp":1519296864000},"page":"1356-1371","source":"Crossref","is-referenced-by-count":84,"title":["HDL in CKD\u2014The Devil Is in the Detail"],"prefix":"10.1681","volume":"29","author":[{"given":"Florian","family":"Kronenberg","sequence":"first","affiliation":[{"name":"Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"B1-20231016","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrneph.2010.36","article-title":"HDL metabolism and activity in chronic kidney disease","volume":"6","author":"Vaziri","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"B2-20231016","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.immuni.2013.02.009","article-title":"Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2","volume":"38","author":"Speer","year":"2013","journal-title":"Immunity"},{"key":"B3-20231016","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/ndt\/15.3.389","article-title":"Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients","volume":"15","author":"Morena","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"B4-20231016","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ki.2009.177","article-title":"In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide","volume":"76","author":"Vaziri","year":"2009","journal-title":"Kidney Int"},{"key":"B5-20231016","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.trsl.2016.02.008","article-title":"Dysfunctional high-density lipoproteins in coronary heart disease: Implications for diagnostics and therapy","volume":"173","author":"Annema","year":"2016","journal-title":"Transl Res"},{"key":"B6-20231016","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40620-016-0278-5","article-title":"Lipotoxicity as a trigger factor of renal disease","volume":"29","author":"Izquierdo-Lahuerta","year":"2016","journal-title":"J Nephrol"},{"key":"B7-20231016","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1681\/ASN.2006091006","article-title":"Lipoprotein metabolism and lipid management in chronic kidney disease","volume":"18","author":"Kwan","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B8-20231016","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1146\/annurev.biochem.68.1.523","article-title":"Charting the fate of the \u201cgood cholesterol\u201d: Identification and characterization of the high-density lipoprotein receptor SR-BI","volume":"68","author":"Krieger","year":"1999","journal-title":"Annu Rev Biochem"},{"key":"B9-20231016","doi-asserted-by":"crossref","first-page":"15886","DOI":"10.1038\/s41598-017-15949-7","article-title":"HDL particles incorporate into lipid bilayers - a combined AFM and single molecule fluorescence microscopy study","volume":"7","author":"Plochberger","year":"2017","journal-title":"Sci Rep"},{"key":"B10-20231016","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.nutr.18.1.297","article-title":"Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport","volume":"18","author":"Bruce","year":"1998","journal-title":"Annu Rev Nutr"},{"key":"B11-20231016","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"B12-20231016","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(15)60608-0","article-title":"The evolving role of CETP inhibition: Beyond HDL cholesterol","volume":"386","author":"Ray","year":"2015","journal-title":"Lancet"},{"key":"B13-20231016","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/ATVBAHA.115.306879","article-title":"Cholesteryl ester transfer protein inhibition is not yet dead--pro","volume":"36","author":"Barter","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B14-20231016","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"B15-20231016","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMe1711407","article-title":"CETP inhibitors - a new inning?","volume":"377","author":"Hegele","year":"2017","journal-title":"N Engl J Med"},{"key":"B16-20231016","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"B17-20231016","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1365-2796.2011.02403.x","article-title":"Genetic variation in HDL-related genes and the association with cardiovascular disease: HDL particles as chameleons of lipoprotein metabolism","volume":"270","author":"Kronenberg","year":"2011","journal-title":"J Intern Med"},{"key":"B18-20231016","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.exger.2008.11.003","article-title":"Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: A systematic in-depth review","volume":"44","author":"Boes","year":"2009","journal-title":"Exp Gerontol"},{"key":"B19-20231016","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"B20-20231016","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.aad3517","article-title":"Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease","volume":"351","author":"Zanoni","year":"2016","journal-title":"Science"},{"key":"B21-20231016","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1681\/ASN.2013111212","article-title":"HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype","volume":"25","author":"Shroff","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B22-20231016","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.2013050482","article-title":"HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction","volume":"25","author":"Zewinger","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B23-20231016","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.V8121889","article-title":"Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients","volume":"8","author":"Koch","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"B24-20231016","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1681\/ASN.2013080816","article-title":"HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients","volume":"26","author":"Silbernagel","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B25-20231016","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1681\/ASN.V1051027","article-title":"The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: A prospective follow-up","volume":"10","author":"Kronenberg","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"B26-20231016","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1046\/j.1523-1755.1999.00273.x","article-title":"Inflammation enhances cardiovascular risk and mortality in hemodialysis patients","volume":"55","author":"Zimmermann","year":"1999","journal-title":"Kidney Int"},{"key":"B27-20231016","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1681\/ASN.V1271516","article-title":"Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: A cross-sectional study","volume":"12","author":"Stack","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"B28-20231016","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1681\/ASN.2006070795","article-title":"Association between serum lipids and survival in hemodialysis patients and impact of race","volume":"18","author":"Kilpatrick","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B29-20231016","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/ndt\/gfu022","article-title":"Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients","volume":"29","author":"Moradi","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B30-20231016","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2215\/CJN.08730816","article-title":"Association of serum triglyceride to HDL cholesterol ratio with all-cause and cardiovascular mortality in incident hemodialysis patients","volume":"12","author":"Chang","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B31-20231016","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2014.02.006","article-title":"Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: The ARIC study","volume":"234","author":"Lamprea-Montealegre","year":"2014","journal-title":"Atherosclerosis"},{"key":"B32-20231016","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1093\/hmg\/ddr580","article-title":"Genetic associations with lipoprotein subfractions provide information on their biological nature","volume":"21","author":"Petersen","year":"2012","journal-title":"Hum Mol Genet"},{"key":"B33-20231016","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11255-016-1466-x","article-title":"Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?","volume":"49","author":"Gluba-Brz\u00f3zka","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"B34-20231016","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2010111144","article-title":"Uremia alters HDL composition and function","volume":"22","author":"Holzer","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B35-20231016","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MNH.0000000000000217","article-title":"Kidneys: Key modulators of high-density lipoprotein levels and function","volume":"25","author":"Yang","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B36-20231016","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1111\/j.1523-1755.2005.09916.x","article-title":"Dyslipidemia and the progression of renal disease in chronic renal failure patients","author":"Cases","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"B37-20231016","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/01.HYP.26.4.670","article-title":"Effects of hypertension and dyslipidemia on the decline in renal function","volume":"26","author":"M\u00e4ntt\u00e4ri","year":"1995","journal-title":"Hypertension"},{"key":"B38-20231016","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1523-1755.2000.00165.x","article-title":"Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study","volume":"58","author":"Muntner","year":"2000","journal-title":"Kidney Int"},{"key":"B39-20231016","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1681\/ASN.2005070733","article-title":"Apolipoprotein A-IV predicts progression of chronic kidney disease: The mild to moderate kidney disease study","volume":"17","author":"Boes","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B40-20231016","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1681\/ASN.V1482084","article-title":"Cholesterol and the risk of renal dysfunction in apparently healthy men","volume":"14","author":"Schaeffner","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"B41-20231016","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2337\/dc12-0306","article-title":"Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: Results of the ADVANCE study","volume":"35","author":"Morton","year":"2012","journal-title":"Diabetes Care"},{"key":"B42-20231016","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.09320913","article-title":"Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study","volume":"9","author":"Rahman","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B43-20231016","doi-asserted-by":"crossref","first-page":"863","DOI":"10.5551\/jat.38612","article-title":"Investigation of metabolic factors associated with eGFR decline over 1 year in a Japanese population without CKD","volume":"24","author":"Hayashi","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"B44-20231016","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.291.7.844","article-title":"Predictors of new-onset kidney disease in a community-based population","volume":"291","author":"Fox","year":"2004","journal-title":"JAMA"},{"key":"B45-20231016","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cca.2011.10.021","article-title":"Independent association of TG\/HDL-C with urinary albumin excretion in normotensive subjects in a rural Korean population","volume":"413","author":"Kang","year":"2012","journal-title":"Clin Chim Acta"},{"key":"B46-20231016","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.atherosclerosis.2013.12.037","article-title":"Association of the triglycerides to high-density lipoprotein cholesterol ratio with the risk of chronic kidney disease: Analysis in a large Japanese population","volume":"233","author":"Tsuruya","year":"2014","journal-title":"Atherosclerosis"},{"key":"B47-20231016","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1053\/j.ajkd.2015.05.011","article-title":"Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: A longitudinal study in a large Japanese population","volume":"66","author":"Tsuruya","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B48-20231016","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.atherosclerosis.2016.06.029","article-title":"LDL-C\/apoB and HDL-C\/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort","volume":"251","author":"Bae","year":"2016","journal-title":"Atherosclerosis"},{"key":"B49-20231016","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.kint.2015.12.034","article-title":"Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression","volume":"89","author":"Bowe","year":"2016","journal-title":"Kidney Int"},{"key":"B50-20231016","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.kint.2016.01.007","article-title":"High-density lipoprotein cholesterol on a roller coaster: Where will the ride end?","volume":"89","author":"Kronenberg","year":"2016","journal-title":"Kidney Int"},{"key":"B51-20231016","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1681\/ASN.2013090965","article-title":"Effects of lowering LDL cholesterol on progression of kidney disease","volume":"25","author":"Haynes","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B52-20231016","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1681\/ASN.2016010098","article-title":"Mendelian randomization as an approach to assess causality using observational data","volume":"27","author":"Sekula","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B53-20231016","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/ATVBAHA.116.308393","article-title":"Is high-density lipoprotein cholesterol causally related to kidney function? Evidence from genetic epidemiological studies","volume":"36","author":"Coassin","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B54-20231016","article-title":"HDL cholesterol, LDL cholesterol, and triglycerides as risk factors for CKD: A Mendelian randomization study [published online ahead of print July 26, 2017]","author":"Lanktree","journal-title":"Am J Kidney Dis"},{"key":"B55-20231016","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ahj.2016.07.005","article-title":"Cholesterol efflux capacity: An introduction for clinicians","volume":"180","author":"Anastasius","year":"2016","journal-title":"Am Heart J"},{"key":"B56-20231016","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1681\/ASN.2014030309","article-title":"Dialysis modalities and HDL composition and function","volume":"26","author":"Holzer","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B57-20231016","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.jacc.2012.09.013","article-title":"Dysfunctional high-density lipoprotein in patients on chronic hemodialysis","volume":"60","author":"Yamamoto","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"B58-20231016","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1161\/ATVBAHA.114.304172","article-title":"Lower Apo A-I and lower HDL-C levels are associated with higher intermediate CD14++CD16+ monocyte counts that predict cardiovascular events in chronic kidney disease","volume":"34","author":"Rogacev","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B59-20231016","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.yjmcc.2017.05.001","article-title":"Plasma metabolite profiles, cellular cholesterol efflux, and non-traditional cardiovascular risk in patients with CKD","volume":"112","author":"Ganda","year":"2017","journal-title":"J Mol Cell Cardiol"},{"key":"B60-20231016","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N Engl J Med"},{"key":"B61-20231016","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"key":"B62-20231016","first-page":"1870","article-title":"HDL cholesterol efflux capacity and cardiovascular events","volume":"372","author":"Ritsch","year":"2015","journal-title":"N Engl J Med"},{"key":"B63-20231016","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2213-8587(15)00126-6","article-title":"Association of HDL cholesterol efflux capacity with incident coronary heart disease events: A prospective case-control study","volume":"3","author":"Saleheen","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B64-20231016","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jacc.2016.10.054","article-title":"HDL cholesterol efflux capacity and cardiovascular events in patients with chronic kidney disease","volume":"69","author":"Bauer","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B65-20231016","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1681\/ASN.2016030262","article-title":"HDL cholesterol efflux does not predict cardiovascular risk in hemodialysis patients","volume":"28","author":"Kopecky","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B66-20231016","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1681\/ASN.2014090857","article-title":"HDL cholesterol efflux predicts graft failure in renal transplant recipients","volume":"27","author":"Annema","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B67-20231016","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/heartjnl-2012-302818","article-title":"Arterial disease in chronic kidney disease","volume":"99","author":"Moody","year":"2013","journal-title":"Heart"},{"key":"B68-20231016","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ncb2210","article-title":"MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins","volume":"13","author":"Vickers","year":"2011","journal-title":"Nat Cell Biol"},{"key":"B69-20231016","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1253\/circj.CJ-13-1025","article-title":"High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis","volume":"77","author":"Annema","year":"2013","journal-title":"Circ J"},{"key":"B70-20231016","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0022-2275(20)33462-3","article-title":"Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3","volume":"41","author":"Navab","year":"2000","journal-title":"J Lipid Res"},{"key":"B71-20231016","doi-asserted-by":"crossref","first-page":"7859","DOI":"10.1016\/S0021-9258(19)39010-6","article-title":"Human apolipoprotein A-IV binds to apolipoprotein A-I\/A-II receptor sites and promotes cholesterol efflux from adipose cells","volume":"265","author":"Steinmetz","year":"1990","journal-title":"J Biol Chem"},{"key":"B72-20231016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0005-2760(86)90337-1","article-title":"The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from an ether analog of phosphatidylcholine","volume":"878","author":"Stein","year":"1986","journal-title":"Biochim Biophys Acta"},{"key":"B73-20231016","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1432-1033.1979.tb13261.x","article-title":"Apolipoprotein A-IV: A protein occurring in human mesenteric lymph chylomicrons and free in plasma. Isolation and quantification","volume":"99","author":"Utermann","year":"1979","journal-title":"Eur J Biochem"},{"key":"B74-20231016","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1172\/JCI109745","article-title":"Human apolipoprotein A-IV. Intestinal origin and distribution in plasma","volume":"65","author":"Green","year":"1980","journal-title":"J Clin Invest"},{"key":"B75-20231016","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1194\/jlr.M300060-JLR200","article-title":"Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls","volume":"44","author":"Ezeh","year":"2003","journal-title":"J Lipid Res"},{"key":"B76-20231016","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/S0021-9258(19)39557-2","article-title":"Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV","volume":"265","author":"Goldberg","year":"1990","journal-title":"J Biol Chem"},{"key":"B77-20231016","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0021-9258(18)89547-3","article-title":"Activation of lecithin: Cholesterol acyltransferase by human apolipoprotein A-IV","volume":"260","author":"Steinmetz","year":"1985","journal-title":"J Biol Chem"},{"key":"B78-20231016","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0022-2275(20)40111-7","article-title":"Comparative effects of purified apolipoproteins A-I, A-II, and A-IV on cholesteryl ester transfer protein activity","volume":"35","author":"Guyard-Dangremont","year":"1994","journal-title":"J Lipid Res"},{"key":"B79-20231016","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.273.5277.966","article-title":"Protection against atherogenesis in mice mediated by human apolipoprotein A-IV","volume":"273","author":"Duverger","year":"1996","journal-title":"Science"},{"key":"B80-20231016","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1172\/JCI119358","article-title":"Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV","volume":"99","author":"Cohen","year":"1997","journal-title":"J Clin Invest"},{"key":"B81-20231016","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2016.04.019","article-title":"Plaque stabilizing effects of apolipoprotein A-IV","volume":"251","author":"Geronimo","year":"2016","journal-title":"Atherosclerosis"},{"key":"B82-20231016","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0735-1097(00)00775-0","article-title":"Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease","volume":"36","author":"Kronenberg","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"B83-20231016","first-page":"275","article-title":"The relationship between plasma apolipoprotein A-IV levels and coronary heart disease","volume":"114","author":"Manpuya","year":"2001","journal-title":"Chin Med J (Engl)"},{"key":"B84-20231016","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1744-9987.2010.00809.x","article-title":"Impact of serum apolipoprotein A-IV as a marker of cardiovascular disease in maintenance hemodialysis patients","volume":"14","author":"Omori","year":"2010","journal-title":"Ther Apher Dial"},{"key":"B85-20231016","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1194\/jlr.M600178-JLR200","article-title":"Role of the kidney in the metabolism of apolipoprotein A-IV: Influence of the type of proteinuria","volume":"47","author":"Lingenhel","year":"2006","journal-title":"J Lipid Res"},{"key":"B86-20231016","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1681\/ASN.V132461","article-title":"Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure","volume":"13","author":"Kronenberg","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B87-20231016","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2796.2012.02585.x","article-title":"Apolipoprotein A-IV concentrations and clinical outcomes in haemodialysis patients with type 2 diabetes mellitus--a post hoc analysis of the 4D Study","volume":"272","author":"Kollerits","year":"2012","journal-title":"J Intern Med"},{"key":"B88-20231016","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/j.1523-1755.2005.00519.x","article-title":"Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue","volume":"68","author":"Haiman","year":"2005","journal-title":"Kidney Int"},{"key":"B89-20231016","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V61110","article-title":"Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis","volume":"6","author":"Kronenberg","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"B90-20231016","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2362.1992.tb01822.x","article-title":"Plasma apolipoprotein A-IV metabolism in patients with chronic renal disease","volume":"22","author":"Dieplinger","year":"1992","journal-title":"Eur J Clin Invest"},{"key":"B91-20231016","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0009-8981(87)90350-0","article-title":"An increased apo A-IV serum concentration of patients with chronic renal failure on hemodialysis","volume":"167","author":"Seishima","year":"1987","journal-title":"Clin Chim Acta"},{"key":"B92-20231016","first-page":"156","article-title":"High serum apolipoprotein AIV levels in renal transplant recipients","volume":"55","author":"Massy","year":"2001","journal-title":"Clin Nephrol"},{"key":"B93-20231016","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1046\/j.1523-1755.63.s84.23.x","article-title":"Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients","volume":"84","author":"Kronenberg","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"B94-20231016","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/joim.12380","article-title":"Association between apolipoprotein A-IV concentrations and chronic kidney disease in two large population-based cohorts: Results from the KORA studies","volume":"278","author":"Stangl","year":"2015","journal-title":"J Intern Med"},{"key":"B95-20231016","first-page":"H1836","article-title":"Apolipoprotein AIV: A potent endogenous inhibitor of lipid oxidation","volume":"274","author":"Qin","year":"1998","journal-title":"Am J Physiol"},{"key":"B96-20231016","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1093\/hmg\/ddw211","article-title":"A genome-wide association meta-analysis on apolipoprotein A-IV concentrations","volume":"25","author":"Lamina","year":"2016","journal-title":"Hum Mol Genet"},{"key":"B97-20231016","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1038\/ncomms10023","article-title":"Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function","volume":"7","author":"Pattaro","year":"2016","journal-title":"Nat Commun"},{"key":"B98-20231016","doi-asserted-by":"crossref","first-page":"8734","DOI":"10.1038\/s41598-017-07213-9","article-title":"Evaluating the causal relation of apoA-IV with disease-related traits - A bidirectional two-sample Mendelian Randomization study","volume":"7","author":"Mack","year":"2017","journal-title":"Sci Rep"},{"key":"B99-20231016","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.2337\/dc17-0911","article-title":"Identification of novel circulating biomarkers predicting rapid decline in renal function in type 2 diabetes: The Fremantle Diabetes study phase II","volume":"40","author":"Peters","year":"2017","journal-title":"Diabetes Care"},{"key":"B100-20231016","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MOL.0000000000000371","article-title":"Apolipoprotein L1 and apolipoprotein A-IV and their association with kidney function","volume":"28","author":"Kronenberg","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"B101-20231016","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4103\/1947-2714.103310","article-title":"Antioxidant and anti-inflammatory role of paraoxonase 1: Implication in arteriosclerosis diseases","volume":"4","author":"Litvinov","year":"2012","journal-title":"N Am J Med Sci"},{"key":"B102-20231016","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African Americans","volume":"329","author":"Genovese","year":"2010","journal-title":"Science"},{"key":"B103-20231016","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00439-010-0861-0","article-title":"Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene","volume":"128","author":"Tzur","year":"2010","journal-title":"Hum Genet"},{"key":"B104-20231016","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.semnephrol.2015.04.008","article-title":"APOL1 kidney disease risk variants: An evolving landscape","volume":"35","author":"Dummer","year":"2015","journal-title":"Semin Nephrol"},{"key":"B105-20231016","doi-asserted-by":"crossref","first-page":"e1005349","DOI":"10.1371\/journal.pgen.1005349","article-title":"In vivo modeling implicates APOL1 in nephropathy: Evidence for dominant negative effects and epistasis under anemic stress","volume":"11","author":"Anderson","year":"2015","journal-title":"PLoS Genet"},{"key":"B106-20231016","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/ki.2015.151","article-title":"Sequencing rare and common APOL1 coding variants to determine kidney disease risk","volume":"88","author":"Limou","year":"2015","journal-title":"Kidney Int"},{"key":"B107-20231016","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000439448","article-title":"Re-sequencing of the APOL1-APOL4 and MYH9 gene regions in African Americans does not identify additional risks for CKD progression","volume":"42","author":"Hawkins","year":"2015","journal-title":"Am J Nephrol"},{"key":"B108-20231016","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","article-title":"APOL1 risk variants, race, and progression of chronic kidney disease","volume":"369","author":"Parsa","year":"2013","journal-title":"N Engl J Med"},{"key":"B109-20231016","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2215\/CJN.01180117","article-title":"APOL1 risk variants, incident proteinuria, and subsequent eGFR decline in blacks with hypertension-attributed CKD","volume":"12","author":"Chen","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B110-20231016","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2215\/CJN.12221115","article-title":"Patterns of kidney function decline associated with APOL1 genotypes: Results from AASK","volume":"11","author":"Tin","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B111-20231016","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/art.38220","article-title":"End-stage renal disease in African Americans with lupus nephritis is associated with APOL1","volume":"66","author":"Freedman","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B112-20231016","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1681\/ASN.2015070763","article-title":"Race, APOL1 risk, and eGFR decline in the general population","volume":"27","author":"Grams","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B113-20231016","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1073\/pnas.1522913113","article-title":"APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases","volume":"113","author":"Olabisi","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B114-20231016","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.2215\/CJN.01330214","article-title":"Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy","volume":"9","author":"Freedman","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B115-20231016","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2215\/CJN.08340814","article-title":"Hemostatic factors, APOL1 risk variants, and the risk of ESRD in the atherosclerosis risk in communities study","volume":"10","author":"Tin","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B116-20231016","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nm.4362","article-title":"A tripartite complex of suPAR, APOL1 risk variants and \u03b1v\u03b23 integrin on podocytes mediates chronic kidney disease","volume":"23","author":"Hayek","year":"2017","journal-title":"Nat Med"},{"key":"B117-20231016","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCRESAHA.114.302347","article-title":"Increased burden of cardiovascular disease in carriers of APOL1 genetic variants","volume":"114","author":"Ito","year":"2014","journal-title":"Circ Res"},{"key":"B118-20231016","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/ATVBAHA.115.305970","article-title":"APOL1 genotype, kidney and cardiovascular disease, and death in older adults","volume":"36","author":"Mukamal","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B119-20231016","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/ki.2014.254","article-title":"Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial","volume":"87","author":"Langefeld","year":"2015","journal-title":"Kidney Int"},{"key":"B120-20231016","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ekir.2017.03.008","article-title":"APOL1 renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention Trial","volume":"2","author":"Freedman","year":"2017","journal-title":"Kidney Int Rep"},{"key":"B121-20231016","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/ATVBAHA.117.309384","article-title":"APOL1 risk variants and cardiovascular disease: Results from the AASK (African American Study of Kidney Disease and Hypertension)","volume":"37","author":"Chen","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B122-20231016","doi-asserted-by":"crossref","first-page":"e0182483","DOI":"10.1371\/journal.pone.0182483","article-title":"Apolipoprotein L1 risk variants associate with prevalent atherosclerotic disease in African American systemic lupus erythematosus patients","volume":"12","author":"Blazer","year":"2017","journal-title":"PLoS One"},{"key":"B123-20231016","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1681\/ASN.2011070668","article-title":"Serum amyloid A in uremic HDL promotes inflammation","volume":"23","author":"Weichhart","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B124-20231016","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1681\/ASN.2013111219","article-title":"Restoration of renal function does not correct impairment of uremic HDL properties","volume":"26","author":"Kopecky","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B125-20231016","first-page":"3007","article-title":"Serum amyloid A: High-density lipoproteins interaction and cardiovascular risk","volume":"36","author":"Zewinger","year":"2015","journal-title":"Eur Heart J"},{"key":"B126-20231016","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2215\/CJN.06560714","article-title":"Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis","volume":"10","author":"Kopecky","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B127-20231016","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.2174\/13816128113196660750","article-title":"Pharmacology and clinical pharmacology of methylarginines used as inhibitors of nitric oxide synthases","volume":"20","author":"Kittel","year":"2014","journal-title":"Curr Pharm Des"},{"key":"B128-20231016","doi-asserted-by":"crossref","first-page":"e001833","DOI":"10.1161\/JAHA.115.001833","article-title":"Asymmetric dimethylarginine and cardiovascular risk: Systematic review and meta-analysis of 22 prospective studies","volume":"4","author":"Willeit","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"B129-20231016","doi-asserted-by":"crossref","first-page":"e0165811","DOI":"10.1371\/journal.pone.0165811","article-title":"Asymmetric and symmetric dimethylarginine as risk markers for total mortality and cardiovascular outcomes: A systematic review and meta-analysis of prospective studies","volume":"11","author":"Schlesinger","year":"2016","journal-title":"PLoS One"},{"key":"B130-20231016","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0140-6736(92)90865-Z","article-title":"Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure","volume":"339","author":"Vallance","year":"1992","journal-title":"Lancet"},{"key":"B131-20231016","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1681\/ASN.2005020179","article-title":"Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study","volume":"16","author":"Fliser","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B132-20231016","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2005010076","article-title":"Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach","volume":"16","author":"Ravani","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B133-20231016","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/ndt\/gfn716","article-title":"Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes","volume":"24","author":"Hanai","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B134-20231016","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1681\/ASN.2013121355","article-title":"Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD","volume":"26","author":"Tripepi","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B135-20231016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000355776","article-title":"Asymmetric dimethylarginine and progression of chronic kidney disease: A one-year follow-up study","volume":"39","author":"Eiselt","year":"2014","journal-title":"Kidney Blood Press Res"},{"key":"B136-20231016","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/ki.2015.199","article-title":"Biomarkers of rapid chronic kidney disease progression in type 2 diabetes","volume":"88","author":"Looker","year":"2015","journal-title":"Kidney Int"},{"key":"B137-20231016","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.numecd.2014.10.016","article-title":"Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression","volume":"25","author":"Testa","year":"2015","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B138-20231016","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/ki.2009.382","article-title":"Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients","volume":"77","author":"Abedini","year":"2010","journal-title":"Kidney Int"},{"key":"B139-20231016","doi-asserted-by":"crossref","first-page":"e6065","DOI":"10.1097\/MD.0000000000006065","article-title":"ADMA predicts major adverse renal events in patients with mild renal impairment and\/or diabetes mellitus undergoing coronary angiography","volume":"96","author":"Heunisch","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"B140-20231016","article-title":"Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease [published online ahead of print November 3, 2017]","author":"Emrich","journal-title":"Clin Res Cardiol"},{"key":"B141-20231016","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/eurheartj\/ehx118","article-title":"Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease","volume":"38","author":"Zewinger","year":"2017","journal-title":"Eur Heart J"},{"key":"B142-20231016","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ki.1996.186","article-title":"Advanced oxidation protein products as a novel marker of oxidative stress in uremia","volume":"49","author":"Witko-Sarsat","year":"1996","journal-title":"Kidney Int"},{"key":"B143-20231016","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.ajkd.2004.09.011","article-title":"Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients","volume":"45","author":"Descamps-Latscha","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"B144-20231016","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1161\/CIRCRESAHA.108.193169","article-title":"Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo","volume":"104","author":"Marsche","year":"2009","journal-title":"Circ Res"},{"key":"B145-20231016","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/j.1523-1755.2004.00926.x","article-title":"Early prediction of IgA nephropathy progression: Proteinuria and AOPP are strong prognostic markers","volume":"66","author":"Descamps-Latscha","year":"2004","journal-title":"Kidney Int"},{"key":"B146-20231016","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/labinvest.2014.90","article-title":"Renal expression of advanced oxidative protein products predicts progression of renal fibrosis in patients with IgA nephropathy","volume":"94","author":"Wang","year":"2014","journal-title":"Lab Invest"},{"key":"B147-20231016","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/ki.2009.322","article-title":"Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms","volume":"76","author":"Zhou","year":"2009","journal-title":"Kidney Int"},{"key":"B148-20231016","doi-asserted-by":"crossref","first-page":"F427","DOI":"10.1152\/ajprenal.90536.2008","article-title":"Advanced oxidation protein products induce mesangial cell perturbation through PKC-dependent activation of NADPH oxidase","volume":"296","author":"Wei","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"B149-20231016","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"B150-20231016","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MOL.0b013e328350a425","article-title":"Lipid-based carriers of microRNAs and intercellular communication","volume":"23","author":"Vickers","year":"2012","journal-title":"Curr Opin Lipidol"},{"issue":"12 Pt B","key":"B151-20231016","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.bbalip.2016.01.011","article-title":"Lipoprotein carriers of microRNAs","volume":"1861","author":"Michell","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"B152-20231016","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/cvr\/cvu140","article-title":"microRNAs and HDL life cycle","volume":"103","author":"Canfr\u00e1n-Duque","year":"2014","journal-title":"Cardiovasc Res"},{"key":"B153-20231016","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/emmm.201201228","article-title":"miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity","volume":"4","author":"Allen","year":"2012","journal-title":"EMBO Mol Med"},{"key":"B154-20231016","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/hep.26427","article-title":"Regulation of cholesterol and bile acid homeostasis by the cholesterol 7\u03b1-hydroxylase\/steroid response element-binding protein 2\/microRNA-33a axis in mice","volume":"58","author":"Li","year":"2013","journal-title":"Hepatology"},{"key":"B155-20231016","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1093\/eurheartj\/ehw146","article-title":"Liver microRNAs: Potential mediators and biomarkers for metabolic and cardiovascular disease?","volume":"37","author":"Willeit","year":"2016","journal-title":"Eur Heart J"},{"issue":"Pt A","key":"B156-20231016","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.fct.2016.02.018","article-title":"MicroRNA biomarkers in clinical renal disease: From diabetic nephropathy renal transplantation and beyond","volume":"98","author":"Nassirpour","year":"2016","journal-title":"Food Chem Toxicol"},{"key":"B157-20231016","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.coph.2016.02.001","article-title":"Targeting non-coding RNA for the therapy of renal disease","volume":"27","author":"Denby","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"B158-20231016","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1681\/ASN.2010040367","article-title":"miR-335 and miR-34a promote renal senescence by suppressing mitochondrial antioxidative enzymes","volume":"22","author":"Bai","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B160-20231016","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1194\/jlr.R035725","article-title":"Proteomic diversity of high density lipoproteins: Our emerging understanding of its importance in lipid transport and beyond","volume":"54","author":"Shah","year":"2013","journal-title":"J Lipid Res"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201805000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:30:34Z","timestamp":1786131034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201805000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":159,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2017070798","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]}}}